Original Article

You have full text access to this OnlineOpen article

External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma

A phase 2 Southwest Oncology Group trial

  1. Deborah T. Blumenthal MD1,2,
  2. Cathryn Rankin MS3,‡‡,*,
  3. Harmon J. Eyre MD4,
  4. Robert B. Livingston MD5,†,
  5. Alexander M. Spence MD5,‡,
  6. Keith J. Stelzer MD, PhD5,§,
  7. Elisabeth J. Rushing MD6,
  8. Mitchel S. Berger MD7,
  9. Saul E. Rivkin MD5,¶,
  10. Allen L. Cohn MD8,‖,
  11. Stephen H. Petersdorf MD5,††

Article first published online: 2 JUN 2008

DOI: 10.1002/cncr.23585

Issue

Cancer

Cancer

Volume 113, Issue 3, pages 559–565, 1 August 2008

Additional Information

How to Cite

Blumenthal, D. T., Rankin, C., Eyre, H. J., Livingston, R. B., Spence, A. M., Stelzer, K. J., Rushing, E. J., Berger, M. S., Rivkin, S. E., Cohn, A. L. and Petersdorf, S. H. (2008), External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma. Cancer, 113: 559–565. doi: 10.1002/cncr.23585

Author Information

  1. 1

    Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah Health Sciences Center, Salt Lake City, Utah

  2. 2

    Neuro-oncology Service, Oncology Division, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

  3. 3

    Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington

  4. 4

    Research and Cancer Control Science, American Cancer Society, Atlanta, Georgia

  5. 5

    Puget Sound Oncology Consortium, Seattle, Washington

  6. 6

    Department of Neuropathology and Ophthalmic Pathology, Armed Forces Institute of Pathology, Washington, DC

  7. 7

    Department of Neurosurgery, University of California at San Francisco, San Francisco, California

  8. 8

    Division of Medical Oncology, University of Colorado Health Sciences Center, Denver, Colorado

  1. †

    Arizona Hemophilia and Thrombosis Center, Arizona Cancer Center, Hematology/Oncology Section, Tucson, Arizona

  2. ‡

    Department of Neurology, University of Washington School of Medicine, Seattle, Washington

  3. §

    Radiation Oncology, Mid-Columbia Medical Center, The Dalles, Oregon

  4. Swedish Cancer Institute, Seattle, Washington

  5. ‖

    Medical Oncology, Rocky Mountain Cancer Centers, Denver, Colorado

  6. ††

    Medical Oncology, Seattle Cancer Care Alliance, Seattle, Washington

  1. ‡‡

    Fax: (734) 998-7118

*Group Chair's Office, Southwest Oncology Group (SWOG-9016), 24 Frank Lloyd Wright Dr., PO Box 483, Ann Arbor, MI 48106-0483

Publication History

  1. Issue published online: 18 JUL 2008
  2. Article first published online: 2 JUN 2008
  3. Manuscript Accepted: 4 MAR 2008
  4. Manuscript Revised: 17 FEB 2008
  5. Manuscript Received: 10 DEC 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (101K)

REFERENCES

  • 1
    Surgical approaches to gliomas.Vandenberg S,Sampaio Lopes MB. Classification. In: BergerMS,WilsonCB, eds. The Gliomas. Philadelphia: W.B. Saunders Company; 1999: 349–360, 172–191.
  • 2
    Burger PC,Vogel FS,Green SB,Strike TA. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer. 1985; 56: 1106–1111.
    Direct Link:
  • 3
    Walker MD,Alexander EJr,Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg. 1978; 49: 333–343.
  • 4
    Walker MD,Green SB,Byar DP, et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303: 1323–1329.
  • 5
    Fine HA,Dear KB,Loeffler JS,Black PM,Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993; 71: 2585–2597.
    Direct Link:
  • 6
    Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359: 1011–1018.
  • 7
    Moynihan TJ,Grossman SA. The role of chemotherapy in the treatment of primary tumors of the central nervous system. Cancer Invest. 1994; 12: 88–97.
  • 8
    DeGregorio M,Wilbur B,King O, et al. Peak cerebrospinal fluid platinum levels in a patient with ependymoma: evaluation of 2 different methods of cisplatin administration. Cancer Treat Rep. 1986; 70: 1437–1438.
  • 9
    Ali-Osman F,Berger MS,Livingston R,Spence A. Cross-resistance patterns of human malignant gliomas to chemotherapeutic agents. Proc Am Soc Clin Oncol. 1989; 8: 86.
  • 10
    Spence AM,Berger MS,Livingston RB,Ali-Osman F,Griffin B. Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J Neurooncol. 1992; 12: 187–191.
  • 11
    Vokes EE,Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990; 8: 911–934.
  • 12
    Weinstein AS,Diener-West M,Nelson DF,Pakuris E. Pulmonary toxicity of carmustine in patients treated for malignant glioma. Cancer Treat Rep. 1986; 70: 943–946.
  • 13
    Kaplan EL,Meier P. Nonparametric observation from incomplete observations. J Am Stat Assoc. 1958; 53: 457–481.
  • 14
    Green S,Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs. 1992; 10: 239–253.
  • 15
    Petersdorf S,Berger M. The molecular basis of chemotherapy. In: RaffelC,HarshG, eds. The Molecular Basis of Neurosurgical Disease. Baltimore: Williams and Wilkins; 1996: 198–210.
  • 16
    Sheline GE. Radiotherapy for high grade gliomas. Int J Radiat Oncol Biol Phys. 1990; 18: 793–803.
  • 17
    Chang CH,Horton J,Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983; 52: 997–1007.
    Direct Link:
  • 18
    Stenning SP,Freedman LS,Bleehen NM. An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer. 1987; 56: 89–90.
  • 19
    Lesser GJ,Grossman S. The chemotherapy of high grade astrocytomas. Semin Oncol. 1994; 21: 220–235.
  • 20
    Levin VA,Silver P,Hannigan J, et al. Superiority of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NOCG 6061 final report. Int J Radiat Oncol Biol Phys. 1990; 18: 321–324.
  • 21
    Prados MD,Scott C,Curran WJJr,Nelson DF,Leibel S,Kramer S. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol. 1999; 17: 3389–3395.
  • 22
    Kleinberg L,Grossman SA,Piantadosi S,Zeltzman M,Wharam M. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Int J Radiat Oncol Biol Phys. 1999; 44: 535–543.
  • 23
    Stupp R,Mason WP,van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987–996.
  • 24
    Hegi ME,Diserens AC,Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997–1003.
  • 25
    Curran WJJr,Scott CB,Horton J, et al. Recursive partitioning analysis of prognostic factors in 3 Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85: 704–710.
  • 26
    Grossman SA,Wharam M,Sheidler V, et al. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol. 1997; 15: 2596–2603.
  • 27
    Gilbert M,O'Neill A,Grossman S, et al. A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Cooperative Oncology Group study (E2393). J Neurooncol. 2000; 47: 145–152.
  • 28
    Grossman SA,O'Neill A,Grunnet M, et al. Phase III study comparing 3 cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol. 2003; 21: 1485–1491.
  • 29
    Buckner JC,Ballman KV,Michalak JC, et al. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol. 2006; 20: 3871–3879.
  • 30
    Cokgor I,Friedman HS,Friedman AH. Chemotherapy for adults with malignant glioma. Cancer Invest. 1999; 17: 264–272.
  • 31
    Vredenburgh JJ,Desjardins A,Herndon JE2nd,Dowell JM,Reardon DA,Quinn JA. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13: 1253–1259.
  • 32
    Westphal M,Hilt DC,Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003; 5: 79–88.
  • 33
    Jaeckle KA,Eyre HJ,Townsend JJ, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998; 16: 3310–3315.
  • 34
    Blumenthal DT,Rankin C,Stelzer K, et al. SWOG S0001: a phase III study of radiation therapy (RT) and O6-benzylguanine (O6-BG) plus BCNU versus RT and BCNU alone for newly diagnosed glioblastoma multiforme (GBM) and gliosarcoma. Abstract TA-04. Presented at Eleventh Annual Meeting of the Society for Neuro-Oncology, Orlando, Florida, November 2006 (platform presentation). Neuro Oncol. 2006; 8: 438.
View Full Article (HTML) Get PDF (101K)